Skip to content
To the full analysis

Sanara MedTech Stock: Key Metrics

SMTI
$32.67Closing price of 19 Nov 2026MEQIRI Score 61 out of 100

Sanara MedTech had an operating margin of 8.9% and a return on invested capital (ROIC) of 15.6% in fiscal 2025.

Margins show how much of revenue is left over, returns on capital how hard the invested money works.

Daily figure as of 20 Nov 2026

Margins

  • Gross margin
  • Operating margin
  • Net margin
Figures as a table
YearGross marginOperating marginNet margin
2006−1.7%−257.1%−328.6%
200764.6%−64.4%−86.1%
2008−43.7%−606.1%−611.1%
2009−283.7%−639.6%−799.4%
201040.9%−337.2%−564.1%
201163.8%−226.9%−576.6%
201232.0%−461.7%−157.2%
201354.1%−169.6%−240.3%
201469.5%−78.3%−86.5%
201573.5%−28.6%−39.8%
201682.9%−4.9%−7.5%
201787.2%1.9%5.3%
201891.3%−8.6%−10.3%
201989.7%−23.3%−23.9%
202089.6%−32.3%−27.9%
202190.4%−30.6%−32.8%
202286.1%−27.3%−17.3%
202387.9%−6.5%−6.6%
202490.6%−7.7%−11.2%
202590.1%8.9%no data

Returns on Capital

  • ROE
  • ROIC
  • ROA
Figures as a table
YearROEROICROA
200649.1%no data−100.0%
200729.9%no data−100.0%
2008200.0%no data−100.0%
2009−99.5%−59.8%−48.2%
2010−100.0%−53.4%−75.7%
2011200.0%no data−100.0%
201248.5%no data−100.0%
2013168.0%no data−100.0%
2014200.0%no data−100.0%
2015105.4%no data−96.3%
201698.3%−58.8%−19.1%
2017200.0%20.1%14.9%
2018−54.0%−29.2%−19.7%
2019−42.5%−38.9%−25.3%
2020−70.8%−53.9%−44.3%
2021−25.9%−65.5%−21.8%
2022−19.0%−43.5%−13.0%
2023−9.6%−7.9%−5.8%
2024−24.5%−10.0%−11.0%
2025no data15.6%no data
Buyback calculator for Sanara MedTech

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.